Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

Shukui Qin,Lu Wen,Junsheng Wang,Wenying Deng,Guifang Zhang,Tongfu Jia,Yi Ba,Haijun Zhong,Jianwei. Yang,Xiaoyan Lin,Yuxian Bai,Yifu He,Zhong Xie,Tienan Yi,Xiang Yuan Wu,Feng Ye,Likun Liu,Yong Huang,Mei Wang,Jin Li

Clinical benefit of continuing apatinib beyond progression in advanced or metastatic gastric cancer.

2018

Shukui Qin
Lu Wen
Junsheng Wang
Wenying Deng
Guifang Zhang
Tongfu Jia
Yi Ba
Haijun Zhong
Jianwei. Yang
Xiaoyan Lin
Yuxian Bai
Yifu He
Zhong Xie
Tienan Yi
Xiang Yuan Wu
Feng Ye
Likun Liu
Yong Huang
Mei Wang
Jin Li

e16020Background: Apatinib has been approved in China for patients (pts) with advanced or metastatic gastric and gastro-esophageal junction adenocarcinoma after at least two lines of systemic chemo...

Keywords:

Oncology
Pathology
Apatinib
Metastatic gastric cancer
Internal medicine
Medicine
Adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations